Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Imatinib Resistant”

80 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 80 results

Testing effectiveness (Phase 2)Study completedNCT00101816
What this trial is testing

Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate

Who this might be right for
Chronic Myeloid LeukemiaBlast Crisis
Bristol-Myers Squibb 124
Large-scale testing (Phase 3)WithdrawnNCT00349518
What this trial is testing

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Who this might be right for
Chronic Myeloid LeukemiaAcute Lymphoblastic Leukemia
Bristol-Myers Squibb
Testing effectiveness (Phase 2)UnknownNCT04709731
What this trial is testing

Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia

Who this might be right for
Chronic Myeloid Leukemia (CML)
Associazione Italiana Pazienti Leucemia Mieloide Cronica 50
Not applicableStudy completedNCT01437202
What this trial is testing

Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia

Who this might be right for
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Asan Medical Center 100
Large-scale testing (Phase 3)Ended earlyNCT02627677
What this trial is testing

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia

Who this might be right for
Chronic Phase Chronic Myeloid Leukemia
Ariad Pharmaceuticals 44
Testing effectiveness (Phase 2)Study completedNCT01323400
What this trial is testing

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)

Who this might be right for
GIST
Centre Leon Berard 81
Not applicableNo Longer AvailableNCT00413270
What this trial is testing

Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals
Large-scale testing (Phase 3)Study completedNCT00154375
What this trial is testing

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

Who this might be right for
Glioblastoma MultiformeAstrocytoma
Novartis Pharmaceuticals 240
Not applicableStudy completedNCT00538109
What this trial is testing

An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase

Who this might be right for
Leukemia, Myeloid, Chronic
King Faisal Specialist Hospital & Research Center 8
Post-approval studies (Phase 4)Study completedNCT00510354
What this trial is testing

Treatment of Patients With Everolimus and Imatinib Mesylate Who Have Progressive Gastro Intestinal Stromal Tumors (GIST) and Are Resistant to Imatinib Mesylate

Who this might be right for
Progressive Gastrointestinal Stromal Tumor
Novartis Pharmaceuticals 28
Not applicableUnknownNCT05895942
What this trial is testing

Exploring the Molecular Mechanism Based on KIT Mutation

Who this might be right for
GIST
Xijing Hospital 190
Testing effectiveness (Phase 2)Looking for participantsNCT01746836
What this trial is testing

Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib

Who this might be right for
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositivePhiladelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00049192
What this trial is testing

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Who this might be right for
Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myelogenous LeukemiaRelapsing Chronic Myelogenous Leukemia
National Cancer Institute (NCI) 43
Not applicableUnknownNCT03862768
What this trial is testing

Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment

Who this might be right for
Gastrointestinal Stromal TumorsSurgery
Shanghai Zhongshan Hospital 92
Testing effectiveness (Phase 2)Study completedNCT00482703
What this trial is testing

Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Who this might be right for
Myeloid Leukemia, Chronic
Bristol-Myers Squibb 23
Early research (Phase 1)Study completedNCT00064233
What this trial is testing

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Who this might be right for
Leukemia
Jonsson Comprehensive Cancer Center 42
Testing effectiveness (Phase 2)Study completedNCT00529763
What this trial is testing

Dasatinib in Imatinib Resistant/Intolerant Chinese CML (Chronic and Advanced Phase) Subjects

Who this might be right for
Leukemia
Bristol-Myers Squibb 121
Early research (Phase 1)Study completedNCT00441155
What this trial is testing

Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

Who this might be right for
Gastrointestinal Stromal Tumors
Novartis Pharmaceuticals 14
Not applicableNo Longer AvailableNCT04518644
What this trial is testing

Nilotinib, for Patients With CML-CP or CML-AP

Who this might be right for
Chronic Myelogenous Leukemia (CML)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT01089595
What this trial is testing

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Who this might be right for
GISTMetastatic Disease
Fox Chase Cancer Center 5
Next Page
50